Immunotherapy Failed You? Here's What's Coming Next | More Powerful & More Targeted!

Why immunotherapy fails for many—and how next-gen treatments (designed by Dr. Chaplin) could change outcomes. #immunotherapy #drugdiscovery #cancertreatment

👉 Get your free guide, '10 Things to Elevate Your Chemo Journey'

👉 Want personalized attention to help you along your individual cancer journey? Explore 1:1 sessions with Dr. Chaplin

👉 Want to find out more about Dr. Chaplin's journey of bringing a cancer drug to market? Explore his innovations

--------------------------------------------
Episode Description:

Many of you have been asking about the drugs that I am developing and this episode is an answer to that.

Immunotherapy can be incredible. It has produced total cures in late-stage metastatic patients who had been told that they were "palliative".

 But it only works for some people.

 And the reason why…
is more complicated than most explanations.

Here’s what’s actually going on:

• why some tumors respond—and others don’t
• what the tumor microenvironment is doing behind the scenes
• why “one pathway” treatments often fail
• and what next-generation immunotherapy is trying to fix

This is one of the biggest gaps in cancer treatment today, and the one I am currently engineering drugs to address.

--------------------------------------------

Inquiries: 

info@elevatingcancertreatment.com

https://elevatingcancertreatment.com

--------------------------------------------

Disclaimer:
The information provided in this podcast is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard or read in this podcast or on this channel.
Reliance on any information provided by Dr. Jay Chaplin or Elevating Cancer Treatment is solely at your own risk. Dr. Jay Chaplin is a scientist and drug developer, not a medical doctor providing patient care. The content presented here reflects general scientific understanding and research, and may not be applicable to your individual health circumstances. Individual medical conditions and treatments vary, and no two situations are exactly alike.
Always consult with your personal healthcare provider before making any decisions about your health or treatment plan.

Transcript

SPEAKER_00 0:00

My last question for you.

SPEAKER_01 0:00

So your last last question for me?

SPEAKER_00 0:03

So setting all of this aside, okay, so we were using only things that are available right now. Right. Right? But if you were to use what you are creating, how would that change things?

SPEAKER_01 0:17

That is a whole different thing. The drugs that I'm working on, there's a family of closely related ones. The drugs that I'm working on. Just to keep your eyes open. The drugs that I'm working on, which is a closely related family of them, are all immunotherapies. They're next generation immunotherapies. They are somewhat similar to what immune checkpoint inhibitors do, like Heatruda and Opdevo, but they are far more focused, they're far more targeted, and they're far more potent. And again, this should allow us to move immunotherapies up and to make them more broadly usable. Hello and welcome to Elevating Cancer Treatment, where we explain the science and debunk myths to help you navigate your health journey. My background is a little different. Beyond educating about cancer, I'm actually designing new drugs that are defining the future of oncology. This direct hands-on experience offers me a very different perspective of how these cancer treatments work on the body, interact with the cancer cells, and cause side effects. And these are insights that I'm excited to share with you. If that sounds interesting, make sure to like this video, subscribe to the channel, and hit that notification bell so you never miss an update. And please share it if you find it useful. I'm Dr. Jay Chaplin. An important reminder, I'm a PhD, not an MD. The information in this video is education and it's not medical advice. Every cancer is unique and no general information applies to everyone. Please remember that. Always consult with your healthcare provider for guidance on your specific situation. And two quick things. First, as a thank you for being here, I've created a free resource, 10 things to elevate your chemo journey, which you can download from the link below. And second, by signing up, you'll also get updates on that innovative cancer treatment I'm working on. I'm confident it represents a significant advancement in immunotherapy. So please take a moment, download your free guide, and join us in shaping the future of cancer treatment. Currently, immunotherapies are in this very weird space where if they work for you, and we have very few diagnostic tests, we have very few ways to figure out if they'll work for you, we have a couple, but nothing terribly predictive. If they work for you, there can be magical results, miraculous results. People with very severe end stage, stage four, disseminated cancer throughout their body, complete recurrences, no evidence of disease, disease doesn't come back. It's happened. When they work, they work incredibly well. They work well for 20 to 40% of people. They fail at some point for a large number of people, and they can cause significant side effects for a small number of people. But if that's you, it's a significant side effect. What we're working on are immunotherapies that are far more targeted. They only go and work where they're needed to work. Side effect profile should be a lot lower, and they're far more potent because they utilize not just one, but multiple modalities, multiple different ways of stimulating the immune system, not just taking off the emergency brake, but also stepping on the gas at the same time. So that would be useful for expanding the options for immunotherapies, getting them to work for more people. The other piece, and this is not our thing, but this is something that I counsel people about, there are other ways to stimulate immune function. There are some natural products, there are off-label drugs, there are some things that you can buy and you can take to stimulate certain immune functions. But again, knowing exactly what you need to stimulate for your particular cancer is a big open hole. Many people don't understand the different components of the immune system. They think about it like a thing. It's not a thing, it's a collection of things, it's a giant collection of different things. You can't stimulate the immune system. You have to stimulate T cells or natural killer cells or monocytes or dendritic cells or innate immunity. You have to know what to stimulate. There is an entire untapped field for immunotherapy of immune engineering that people haven't looked into. For instance, with osteosarcoma, in many cases, immunotherapies do poorly with osteosarcoma. That's not necessarily about the particular drugs, it's that we're only hitting one pathway and we need to hit several. Osteosarcomas tend to have a lot of TGF beta, they tend to have a lot of T cells, they tend to have a fibrotic component around the tumor that physically protects it. It's like a wall around a fortress. There are ways to deal with all of those. Some of them are off-label drugs, some of them are natural products, some of them are other approaches. But you usually need to do multiple approaches in order to get those things to work in those hostile environments like osteosarcoma. I wish more people understood that so that we could start pushing in that direction. What we have is we have a situation where Kitruda doesn't work in osteosarcoma, so we're not doing it. Which is true, but it's the most simplistic understanding of a complex system. We know what the issues with immunotherapy and osteosarcoma are, and they can be addressed, but we're not addressing them because the first approach didn't work perfectly. So we're just giving up. It's not a good way to go. And this is not particular to osteosarcoma. There are many other cancers that are like this. If we engineer the tumor microenvironment properly, we can open up efficacy for immunotherapies in a way that currently is not being tapped. We think we've got an approach for that. There are many others as well.

SPEAKER_00 5:42

We meaning you. I don't. I'm not the scientist in the family. I'm the techie person.

SPEAKER_01 5:49

You're our IT person. You're the one who tries to keep me positive when I'm bitterly frustrated.

SPEAKER_00 5:53

Yes. Well, it's only because you care so much. You want it to be better. Yeah.

SPEAKER_01 5:57

Well, and it can be better. It should be better. We have all the tools for it to be better, and it's frankly just habit that it's not.

SPEAKER_00 6:04

So that's the piece that you want to do is engineer the immunotherapies better or more have them be more targeted? And that's what you have to do.

SPEAKER_01 6:13

Have them make more sense.

SPEAKER_00 6:15

Is a technique?

SPEAKER_01 6:16

A set of molecules that incorporate multiple different features. There's one that gets it specifically to where it needs to go and doesn't just roam throughout the body causing havoc. So that's fewer side effects. Once it's there, it's more potent because it delivers a second kind of stimulus at the exact same time. And it's a stimulus that makes sense, unlike a lot of the garbage that we're seeing going into clinical trials right now, where two completely different molecules are fused together that don't have any relationship to each other. That's just bonkers. And then third, there's a technique embedded in the in these protein constructs to bind and stimulate memory helper T cells to re-engineer the entire tumor microenvironment and make cold tumors hot. So we've got a combination molecule, one single molecule that blocks checkpoints like Kichruda does, puts on the gas stimulates the immune system like IL-2 and IL-15 and Antiva do, and at the same time re-engineers the microenvironment and turns the cold tumors hot persistently. I'm not giving away any details. If you want to know the details to that, you'll have to sign a confidentiality agreement. Beyond these videos, if you need more personalized guidance or a deeper dive into specific treatments to have your treatment be as effective as possible, I offer one-on-one sessions and medical advocacy. You can find information on our website, which is linked down below. Again, if you found this video informative, please give it a thumbs up, click the notification bell, and subscribe to our channel for more science based cancer insights.

SPEAKER_00 7:49

I think we are Muppets. I was about to say I am a Muppet. I am a Muppet.